Article
Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib.
Thoracic cancer - 1 Oct 2022
Teranishi Shuhei, Sugimoto Chihiro, Nagaoka Satoshi, Nagayama Hirokazu, Segawa Wataru, Miyasaka Atsushi, Hiro Shuntaro, Kajita Yukihito, Maeda Chihiro, Kobayashi Nobuaki, Yamamoto Masaki, Kudo Makoto, Kaneko Takeshi
Abstract excerpt
BACKGROUND: Clinically measurable factors affecting the progression-free survival (PFS) of patients receiving osimertinib as first-line therapy for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC) have not yet been established. METHODS: We retrospectively reviewed the medical records of 61 patients treated with osimertinib as primary therapy for EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.